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IL-6 for 48hours. CD40, CD80, CD83, CD86, DC-SIGN and HLA-DR
expression was evaluated before and after the HIV-1-stimulation
and IL-12 concentration were measured by ELISA. HIV-1-speciﬁc
lymphoproliferation was analyzed by ﬂow cytometry in 6-day
cocultures of MDDC and lymphocytes. Nonparametric tests were
employed (p<0,05).
Results: The %mDC wasn’t different among groups (medians:
1.9% for AP, 2.45% for VP and 1.95% for controls; Kruskal-Wallis test,
p=0.071) and there was a difference of %pDC between patients and
controls (medians: 0.3% for AP, 0.1% for VP and 0.3% for controls;
Kruskal-Wallis test, p=0.038). VL inversely correlated with %pDC
(Spearman’s rho=-0.314; p=0.016) and mDC inversely correlated
with %CD4 (Spearman’s rho=-0.390; p=0.003).
Before HIV stimulation, MDDC from VP had high level of CD83
expression than controls (p=0.011). After HIV stimulation, MDDC
from all groups had higher HLA-DR, CD40, CD80, CD83 and CD86
and lower DC-SIGN expression. We didn’t ﬁnd a difference in
IL-12 concentration among groups (medians: 2053.8pg/mL for
AP, 2458.4pg/mL for VP and 1626.2pg/mL for controls; Kruskal-
Wallis test, p=0.539). Higher HIV-speciﬁc proliferation was found
in patients with AP in comparison to VP (medians: 12.4% for AP and
0.69% for VP; Mann-Whitney test, p=0.006).
Conclusion:Therefore, in childrenunderART, viremiawas asso-
ciated with lower %pDC, altered MDDC phenotype and reduced
HIV-speciﬁc lymphoproliferation.
http://dx.doi.org/10.1016/j.ijid.2014.03.1030
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Background: Adherence to anti-retroviral therapy (ART) is
lower during adolescence than during any other time of life, and
adolescents have worse immunological and virological outcomes
than adults and children. As a result of the ART rollout in 2004, the
current generation of vertically-infected South African adolescents
is the ﬁrst to survive beyond childhood. However, the rollout came
too late formany of their parents, and as a resultmany are orphans.
Anecdotal evidence supports the impression of frequent household
disruptions and multiple consecutive caregivers for many of these
patients. We aimed to investigate the impact of number of consec-
utive caregivers since start of ART, identity of the current caregiver
and orphan status on virological outcomes and ART regimen.
Methods & Materials: We did a retrospective review of medi-
cal records in the Groote Schuur Hospital Adolescent HIV clinic in
Cape Town, South Africa. We enrolled 203 subjects (54% male, 46%
female) aged between 10 - 19 years, all vertically-infectedwithHIV
and on ART > 1 year. Our primary outcomes were viral load (</>40)
and ART regimen (1st/ 2nd or 3rd line). These were analysed in rela-
tion to number of consecutive caregivers since start of ART, identity
of the current caregiver, and orphan status.
Results: Orphanhood stands at 51% in this setting, and orphans
have the highest rate of caregiver turnover. However, orphanhood
itself was not signiﬁcantly associated with a detectable viral load
or second-line ART regimen. A higher number of caregivers was
associated with a detectable viral load in males (p=0.05), but not
in females. Number of caregivers was not signiﬁcantly associated
with type of ART regimen. An aunt as caregiver was strongly asso-
ciated with having a detectable viral load (p=0.003), but no other
caregiver types yielded signiﬁcant associations. Adolescents who
stay in foster homes were signiﬁcantly more likely to be on a ﬁrst-
line ART regimen (p=0.03), but other types of caregivers showed no
association with treatment regimen.
Conclusion: Complex factors within the family impact on ART
adherence during adolescence. We recommend support for inter-
ventions that assist the struggling extended family to care for
HIV-infected adolescents on a long-term basis.
http://dx.doi.org/10.1016/j.ijid.2014.03.1031
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Background: Artemisinin-based Combination Therapy (ACT) in
Nigeria is inﬂuenced by the increasing prevalence of consistent
resistant-malaria. However, there is limited acceptability by nurs-
ing mothers of children aged 0-5 years regarding ACT. This study
actually assessed the management of malaria in children aged 0-5
years in Nigeria.
Methods & Materials: The study was a cross sectional in design
involving the use of a multistage random sampling technique to
select participants in their households. The questionnaire used
for data collection was validated before its application. Therefore
descriptive and Chi-square statistics were adopted in data analysis
using SPSS data Package software.
Results: Participants’ mean age was 25±5.3 years. Very few had
higher education (4.9%). Some of the participants (30%) had never
used ACT while their major source of acquiring ACT was through
healthcare workers (26.0%) p<0.05. equally, very few of the partic-
ipants (10.0%) had ever used ACT drugs, while 70.0% are current
users of Chloroquine which is the most popularly used (24.2%)
among the malaria drugs. The level of education of the current
users is inconsistent with their knowledge which were as low as
secondary (22.5%) against higher institutions (10.7%) p<0.05. Most
(90.6%) obtained ACT drugs from public health facility where ACT
are administered free of charge to childrenunderﬁve years. Though
participants asserted that the ACT drugs are never expensive, but
a few (27.0%) of the participants were of the opinion that ACT was
very effective than Chloroquine while 80% of the users are in line
with the same view. However, slightly more than half (59%) of
the participants representing few (18.0%) of the total population
agreed that the drugs were readily available. Interestingly most
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(78.0%) could correctly statehowACTcouldbeused inmanagement
malaria in children under ﬁve.
Conclusion: Due to high level of unacceptability and affordabil-
ity ACT adoption for management of malaria in children less than
ﬁve years is still at startling level among their mothers. However,
ACT drugs should be made acceptable, affordable and available by
government and partners in management of malaria among chil-
dren in Africa.
http://dx.doi.org/10.1016/j.ijid.2014.03.1032
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Background: APOBEC3G potently controls HIV replication by
introducing G-to-A hypermutation. Genetic variants of APOBEC3G,
186H/R is associated with HIV/AIDS disease progression in adults.
However, the details of its effect in children remain unclear.
Methods & Materials: Rapid progressors (RPs) was deﬁned as
children who had AIDS-related symptoms (PCP, HIV encephalo-
pathy) before their second birthday. Long-term non-progressors
(LTNPs) were deﬁned as children, aged>8 years, maintaining
CD4%≥25%, and without cART. RPs and LTNPs were of 630 perina-
tally infected childrenwhowere enrolled in themulticenter studies
of Thailand and Cambodia.
APOBEC3G genotypes were determined by PCR-restriction frag-
ment length polymorphism method using genomic DNA samples.
APOBEC3G-mediated hypermutations were analyzed by sequenc-
ing of the vif/vpu genes from proviral DNAs.
Results: A total of 14 RPs and 24 LTNPs were enrolled. 50% of RP
and67%of LTNPwere female (p=0.3).Median ages at sample collec-
tion were 11.6 (4.7-15.1) years and 11.3 (10.0-12.3) years (p=0.3),
for the RPs and LTNPs, respectively. In the RP group, median age at
the ﬁrst AIDS-related symptom was 0.7 (0.4-1.2) years.
Frequency of APOBEC3G 186H/R genotypes, AA:AG:GG, in the
RPs was 100:0:0% whereas 83:17:0% (p=0.3) in the LTNPs. Hyper-
mutation of the vif-coding region were observed in none of the RP
and 12% of the LTNP (p=0.5). In contrast, hypermutations at the vpu
genes were not detected in both groups’ proviral DNAs.
Conclusion: We observed no signiﬁcant associations of the
APOBEC3G genotypes and G-to-A hypermutation rates between
Asian children with different proﬁles of HIV/AIDS disease progres-
sion.
http://dx.doi.org/10.1016/j.ijid.2014.03.1033
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Background: Atazanavir/ritonavir(ATV/r) and tenofovir diso-
proxil fumarate(TDF) are recommended once-daily antiretroviral
therapy, particularly for second-line therapy. Their concomitant
use can lead to decrease in ATV and increase in TDF plasma con-
centration. There are limited data of efﬁcacy and safety of their
co-administration in children and adolescents.
Methods & Materials: Nineteen HIV-infected Thai children
aged 6-18years, body weight 25-50kg, and total bilirubin<2mg/dL
were enrolled. They were either PI-experienced with HIV-
RNA<50copies/ml or PI-naïve with HIV-RNA≥1,000copies/ml.
ATV(Reyataz®) 200mg/capsule with generic ritonavir
100mg/tablet, produced by the Thai Government Pharmaceutical
Organization, were co-administered with TDF and lamivudine
once daily. CD4, HIV-RNA, total bilirubin, creatinine, lipids, lumbar
